Identification of Potential Lead Compound as Promising SARS Covid-2 Inhibitors Using Structure Based Drug Design

Author:

KR Kavya1,V Ajeesh2

Affiliation:

1. Al Shifa College of Pharmacy

2. Ikon Pharmacy College

Abstract

Abstract SARS-CoV−2 has surpassed other coronaviruses in transmission rate, reproduction number, and global deaths, but its case fatality rate remains low. The receptor-binding domain (RBD) of SARS-CoV−2 interacts to human angiotensin-converting enzyme 2 (ACE2) to promote fusion between the S protein and the human cell membrane, boosting the infectivity of the virus. The virtual screening of plant flavonoids offers fresh insight for the treatment of covid, while the majority of allopathic medicines have failed to totally recover. In this study, we sought to develop an alkaloid that can interact competitively with the catalytic regions of SARS COV 2 binding proteins, TMPRSS2 and inhibit the growth of the covid virus.

Publisher

Research Square Platform LLC

Reference18 articles.

1. de Wit, E., van Doremalen, N., Falzarano, D. and Munster, V.J. (2016). SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology, [online] 14(8), pp.523–534.

2. Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., Zhu, H., Zhao, W., Han, Y. and Qin, C. (2019). From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses, [online] 11(1), p.59. Available at: https://www.mdpi.com/1999-4915/11/1/59/htm.

3. Structure, Function, and Evolution of Coronavirus Spike Proteins;Li F;Annual Review of Virology,2016

4. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies;Ragia G;European Journal of Clinical Pharmacology,2020

5. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X. and Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, [online] 395(10223). Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3